{"id":"anti-cd22-car","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This CAR-T cell therapy targets CD22, a protein expressed on the surface of B cells, to selectively kill cancer cells.","oneSentence":"Chimeric antigen receptor targeting CD22","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:52:40.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell malignancies"}]},"trialDetails":[{"nctId":"NCT05674175","phase":"PHASE1, PHASE2","title":"Co-administration of CART22-65s and huCART19 for B-ALL","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2023-01-25","conditions":"B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma","enrollment":93},{"nctId":"NCT02315612","phase":"PHASE1","title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"NHL, Large Cell Lymphoma, Follicular Lymphoma","enrollment":134},{"nctId":"NCT07135466","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies","status":"RECRUITING","sponsor":"Sheba Medical Center","startDate":"2026-02-01","conditions":"B Cell Malignancies","enrollment":50},{"nctId":"NCT07166419","phase":"PHASE1","title":"Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-02-01","conditions":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT02650414","phase":"PHASE1","title":"CD22 Redirected Autologous T Cells for ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2016-01-13","conditions":"B Cell Leukemias, B Cell Lymphomas","enrollment":41},{"nctId":"NCT04815356","phase":"PHASE1","title":"Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hairy Cell Leukemia, Hairy Cell Leukemia Variant","enrollment":27},{"nctId":"NCT03620058","phase":"PHASE1","title":"CART22 Alone or in Combination With huCART19 for ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2018-09-27","conditions":"Chemotherapy Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":23},{"nctId":"NCT04150497","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","status":"RECRUITING","sponsor":"Cellectis S.A.","startDate":"2019-10-14","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":52},{"nctId":"NCT07162571","phase":"PHASE1, PHASE2","title":"This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.","status":"NOT_YET_RECRUITING","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2026-01-01","conditions":"Acute Lymphobkastic Leukemia, B Cell Lymphoma","enrollment":17},{"nctId":"NCT05607420","phase":"PHASE1, PHASE2","title":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Cellectis S.A.","startDate":"2022-11-01","conditions":"B-cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":80},{"nctId":"NCT06005649","phase":"PHASE1, PHASE2","title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","status":"WITHDRAWN","sponsor":"Juventas Cell Therapy Ltd.","startDate":"2025-09","conditions":"Non-hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03287817","phase":"PHASE1, PHASE2","title":"Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","status":"TERMINATED","sponsor":"Autolus Limited","startDate":"2017-09-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":52},{"nctId":"NCT04848493","phase":"","title":"National Project on Vaccines, COVID-19 and Frail Patients","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-19","conditions":"COVID-19, Solid Tumor, Hematologic Diseases","enrollment":747},{"nctId":"NCT03448393","phase":"PHASE1","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-26","conditions":"Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma","enrollment":54},{"nctId":"NCT04340167","phase":"PHASE2","title":"Study of Anti-CD22 CAR-T Cells Treating Leukemia Children","status":"COMPLETED","sponsor":"Beijing Boren Hospital","startDate":"2020-05-01","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT05418088","phase":"PHASE1","title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","status":"RECRUITING","sponsor":"Sumithira Vasu","startDate":"2022-06-30","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia","enrollment":54},{"nctId":"NCT06834529","phase":"PHASE1, PHASE2","title":"CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2025-01-20","conditions":"Relapsed or Refractory B Cell Leukemia and Lymphoma","enrollment":20},{"nctId":"NCT05651178","phase":"EARLY_PHASE1","title":"Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients","status":"RECRUITING","sponsor":"Hrain Biotechnology Co., Ltd.","startDate":"2022-08-12","conditions":"Central Nervous System Lymphoma","enrollment":10},{"nctId":"NCT04340154","phase":"PHASE2","title":"Study of Sequential CAR-T Cell Treating Leukemia Children","status":"TERMINATED","sponsor":"Beijing Boren Hospital","startDate":"2020-05-01","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia","enrollment":81},{"nctId":"NCT05094206","phase":"PHASE1","title":"CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2022-06-30","conditions":"B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia","enrollment":4},{"nctId":"NCT03098355","phase":"PHASE1, PHASE2","title":"Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies","status":"WITHDRAWN","sponsor":"Zhujiang Hospital","startDate":"2017-12-30","conditions":"B-Cell Leukemia, B-Cell Lymphoma","enrollment":""},{"nctId":"NCT03919526","phase":"PHASE1","title":"Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2019-08-11","conditions":"MRD-positive, Acute Lymphoblastic Leukemia","enrollment":19},{"nctId":"NCT05523661","phase":"PHASE1","title":"Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-01","conditions":"Ph Positive ALL, CAR-T Cell, Dasatinib","enrollment":15},{"nctId":"NCT04029038","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-15","conditions":"CD19 Positive, CD22 Positive, Minimal Residual Disease","enrollment":""},{"nctId":"NCT02588456","phase":"PHASE1","title":"Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2015-10","conditions":"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT05797948","phase":"NA","title":"GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-07-01","conditions":"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT05429905","phase":"PHASE1, PHASE2","title":"Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia","status":"UNKNOWN","sponsor":"KK Women's and Children's Hospital","startDate":"2022-07-18","conditions":"Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children","enrollment":48},{"nctId":"NCT04499573","phase":"PHASE1, PHASE2","title":"Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2020-07-27","conditions":"B-ALL","enrollment":50},{"nctId":"NCT05651100","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Kecellitics Biotech Company Ltd","startDate":"2022-12-10","conditions":"Lymphoma, B-Cell","enrollment":50},{"nctId":"NCT05106946","phase":"PHASE1","title":"Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma","status":"UNKNOWN","sponsor":"Fundamenta Therapeutics, Ltd.","startDate":"2021-10-25","conditions":"B-cell Malignancy","enrollment":20},{"nctId":"NCT05091541","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2021-10-20","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":125},{"nctId":"NCT04556669","phase":"PHASE1","title":"Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors","status":"UNKNOWN","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2020-08-01","conditions":"Solid Tumor, Adult, Cervical Cancer, Sarcoma","enrollment":30},{"nctId":"NCT03262298","phase":"PHASE1, PHASE2","title":"Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2017-08-20","conditions":"Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT04601181","phase":"PHASE1","title":"Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies","status":"UNKNOWN","sponsor":"Fundamenta Therapeutics, Ltd.","startDate":"2020-10-23","conditions":"B Cell Malignancy","enrollment":20},{"nctId":"NCT04516551","phase":"PHASE1","title":"Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2020-11-20","conditions":"Relapsed Adult ALL, B Cell Leukemia","enrollment":18},{"nctId":"NCT04430530","phase":"PHASE1, PHASE2","title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","status":"UNKNOWN","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2020-06-01","conditions":"CD19 Negative B-cell Malignancies","enrollment":100},{"nctId":"NCT04303247","phase":"EARLY_PHASE1","title":"CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2020-05-01","conditions":"B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":30},{"nctId":"NCT04303520","phase":"PHASE1","title":"Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine","startDate":"2018-05-03","conditions":"CD19-positive ALL","enrollment":20},{"nctId":"NCT04163575","phase":"PHASE1, PHASE2","title":"Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL","status":"UNKNOWN","sponsor":"Kecellitics Biotech Company Ltd","startDate":"2020-02-01","conditions":"Leukemia, Lymphoma","enrollment":100},{"nctId":"NCT04007978","phase":"PHASE1","title":"Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-08-05","conditions":"B Cell Lymphoma, Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT02935153","phase":"PHASE1, PHASE2","title":"A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies","status":"UNKNOWN","sponsor":"Southwest Hospital, China","startDate":"2016-10","conditions":"Leukemia, Lymphoma","enrollment":45},{"nctId":"NCT03185494","phase":"PHASE1, PHASE2","title":"Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-08-01","conditions":"Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT03824964","phase":"EARLY_PHASE1","title":"Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Allife Medical Science and Technology Co., Ltd.","startDate":"2019-02-01","conditions":"Refractory B-Cell Lymphoma","enrollment":10},{"nctId":"NCT03692767","phase":"EARLY_PHASE1","title":"Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma","status":"UNKNOWN","sponsor":"Allife Medical Science and Technology Co., Ltd.","startDate":"2019-03","conditions":"Refractory B-Cell Lymphoma","enrollment":9},{"nctId":"NCT02721407","phase":"PHASE1","title":"Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2016-03","conditions":"Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT02794961","phase":"PHASE1, PHASE2","title":"CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies","status":"UNKNOWN","sponsor":"Kai Lin Xu; Jun Nian Zheng","startDate":"2016-06","conditions":"Recurrent or Refractory B Cell Malignancy","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":":Anti-CD22-CAR","genericName":":Anti-CD22-CAR","companyName":"Kecellitics Biotech Company Ltd","companyId":"kecellitics-biotech-company-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Chimeric antigen receptor targeting CD22 Used for B-cell malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}